Mostrar el registro sencillo del ítem
dc.contributor.author | Burgos-Simon, Clara | es_ES |
dc.contributor.author | García-Medina, N. | es_ES |
dc.contributor.author | Martínez-Rodríguez, David | es_ES |
dc.contributor.author | Villanueva Micó, Rafael Jacinto | es_ES |
dc.date.accessioned | 2020-12-19T04:31:51Z | |
dc.date.available | 2020-12-19T04:31:51Z | |
dc.date.issued | 2019-11-30 | es_ES |
dc.identifier.issn | 0170-4214 | es_ES |
dc.identifier.uri | http://hdl.handle.net/10251/157499 | |
dc.description.abstract | [EN] Bladder cancer is one of the most common malignant diseases in the urinary system and a highly aggressive neoplasm. The prognosis is not favorable usually, and its evolution for particular patients is very difficult to find out. In this paper, we propose a dynamic mathematical model that describes the bladder tumor growth and the immune response evolution. This model is customized for a single patient, determining appropriate model parameter values via model calibration. Due to the uncertainty of the tumor evolution, using the calibrated model parameters, we predict the tumor size and the immune response evolution over the next few months assuming three different scenarios: favorable, neutral, and unfavorable. In the former, it is not expected any trace of the cancer in the middle of September 2018 (after 16 mo). In the neutral scenario, at the same date, a 7- to 8-mm tumor is expected. In the worst case, a 40-mm tumor is expected. The patient was cited on 10 September 2018 to check the tumor size, and according to the doctors, there was no sign of recurrence. It seems that we are in the favorable scenario. The patient will be called again for follow-up in mid-2019. | es_ES |
dc.description.sponsorship | This work has been supported by the Ministerio de Economía, Industria y Competitividad grant MTM2017-89664-P. | es_ES |
dc.language | Inglés | es_ES |
dc.publisher | John Wiley & Sons | es_ES |
dc.relation.ispartof | Mathematical Methods in the Applied Sciences | es_ES |
dc.rights | Reserva de todos los derechos | es_ES |
dc.subject | Bladder cancer | es_ES |
dc.subject | Cancer prognosis | es_ES |
dc.subject | Dynamic model | es_ES |
dc.subject | Model calibration | es_ES |
dc.subject | Uncertainty quantification | es_ES |
dc.subject.classification | MATEMATICA APLICADA | es_ES |
dc.title | Mathematical modeling of the dynamics of the bladder cancer and the immune response applied to a patient: Evolution and short-term prediction | es_ES |
dc.type | Artículo | es_ES |
dc.identifier.doi | 10.1002/mma.5536 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016/MTM2017-89664-P/ES/PROBLEMAS DINAMICOS CON INCERTIDUMBRE SIMULABLE: MODELIZACION MATEMATICA, ANALISIS, COMPUTACION Y APLICACIONES/ | es_ES |
dc.rights.accessRights | Abierto | es_ES |
dc.contributor.affiliation | Universitat Politècnica de València. Departamento de Matemática Aplicada - Departament de Matemàtica Aplicada | es_ES |
dc.contributor.affiliation | Universitat Politècnica de València. Instituto Universitario de Matemática Multidisciplinar - Institut Universitari de Matemàtica Multidisciplinària | es_ES |
dc.description.bibliographicCitation | Burgos-Simon, C.; García-Medina, N.; Martínez-Rodríguez, D.; Villanueva Micó, RJ. (2019). Mathematical modeling of the dynamics of the bladder cancer and the immune response applied to a patient: Evolution and short-term prediction. Mathematical Methods in the Applied Sciences. 42(17):5746-5757. https://doi.org/10.1002/mma.5536 | es_ES |
dc.description.accrualMethod | S | es_ES |
dc.relation.publisherversion | https://doi.org/10.1002/mma.5536 | es_ES |
dc.description.upvformatpinicio | 5746 | es_ES |
dc.description.upvformatpfin | 5757 | es_ES |
dc.type.version | info:eu-repo/semantics/publishedVersion | es_ES |
dc.description.volume | 42 | es_ES |
dc.description.issue | 17 | es_ES |
dc.relation.pasarela | S\380181 | es_ES |
dc.contributor.funder | Agencia Estatal de Investigación | es_ES |
dc.description.references | Official Site for Spanish Medic Oncology Society.https://www.seom.org. Accessed: 25/09/2018. | es_ES |
dc.description.references | Greenlee, R. T., Hill-Harmon, M. B., Murray, T., & Thun, M. (2001). Cancer Statistics, 2001. CA: A Cancer Journal for Clinicians, 51(1), 15-36. doi:10.3322/canjclin.51.1.15 | es_ES |
dc.description.references | Holmang, S., Hedelin, H., Anderstrom, C., & Johansson, S. L. (1995). The Relationship Among Multiple Recurrences, Progression and Prognosis of Patients with Stages TA and T1 Transitional Cell Cancer of the Bladder Followed for at least 20 years. Journal of Urology, 153(6), 1823-1827. doi:10.1016/s0022-5347(01)67321-x | es_ES |
dc.description.references | Redelman-Sidi, G., Glickman, M. S., & Bochner, B. H. (2014). The mechanism of action of BCG therapy for bladder cancer—a current perspective. Nature Reviews Urology, 11(3), 153-162. doi:10.1038/nrurol.2014.15 | es_ES |
dc.description.references | Bladder Cancer Treatment (PDQ)‐Health Professional Version.https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq. Accessed: 25/09/2018. | es_ES |
dc.description.references | Bladder Cancer Treatment (PDQ)‐Patient Version.https://www.cancer.gov/types/bladder/patient/bladder-treatment-pdq. Accessed: 25/09/2018. | es_ES |
dc.description.references | Official Site for Hospital Universitari i Politècnic La Fe Valencia Spain.http://www.hospital-lafe.com. Accessed: 25/09/2018. | es_ES |
dc.description.references | Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of Cancer: The Next Generation. Cell, 144(5), 646-674. doi:10.1016/j.cell.2011.02.013 | es_ES |
dc.description.references | Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., … Chen, L. (2002). Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nature Medicine, 8(8), 793-800. doi:10.1038/nm730 | es_ES |
dc.description.references | Fernandez, N. C., Lozier, A., Flament, C., Ricciardi-Castagnoli, P., Bellet, D., Suter, M., … Zitvogel, L. (1999). Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo. Nature Medicine, 5(4), 405-411. doi:10.1038/7403 | es_ES |
dc.description.references | Factsheet of OncoTICE 2 − 8 × 108UFC powder for suspension intravesical (in Spanish).https://www.aemps.gob.es/cima/pdfs/es/ft/61377/61377_ft.pdf. Accessed: 25/09/2018. | es_ES |